Ipsen

Actualités

Reuters - Il y a 2 jours

Ipsen Ups FY Guidance, Posts Q3 Revenue Of EUR 836.6 Mln

BRIEF-Ipsen Ups FY Guidance, Posts Q3 Revenue Of EUR 836.6 Mln Oct 23 (Reuters) - Ipsen SA IPN.PA : IPSEN DELIVERS STRONG SALES MOMENTUM IN THE FIRST NINE MONTHS OF 2024 AND INCREASES ITS FULL-YEAR GUIDANCE Q3 REVENUE EUR 836.6 MILLION INCREASED 2024 FINANCIAL GUIDANCE 2024 GUIDANCE: TOTAL-SALES GROWTH GREATER THAN 8.0%, AT CONSTANT CURRENCY (PRIOR

Reuters - Il y a 3 jours

US FDA declines to approve Camurus' rare hormone disorder drug

US FDA declines to approve Camurus' rare hormone disorder drug Oct 22 (Reuters) - The U.S. Food and Drug Administration has declined to approve Camurus' CAMX.ST drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugmaker said late Monday. WHY IT'S IMPORTANT The FDA's decision could delay the approval and subsequent launch of the drug, CAM2029, meant to treat patients with acromegaly, which is diagnosed in three to 14 of ev

Reuters - Il y a 2 semaines

UK's MHRA Says Elafibranor Approved To Treat Adults With A Rare Liver Disease Known As Primary Biliary Cholangitis (Oct. 8)

CORRECTED-(OFFICIAL)-BRIEF-UK's MHRA Says Elafibranor Approved To Treat Adults With A Rare Liver Disease Known As Primary Biliary Cholangitis (Oct. 8) Corrects Oct. 8 brief to remove reference to Elafibranor being approved as "first medicine" in headline and bullet after MHRA clarification Oct 15 (Reuters) - UK's MHRA: UK'S MHRA: ELAFIBRANOR APPROV

Reuters - Il y a 1 mois

Ipsen’s Iqirvo Receives European Approval

BRIEF-Ipsen’s Iqirvo Receives European Approval Sept 20 (Reuters) - Ipsen SA IPN.PA : IPSEN’S IQIRVO® (ELAFIBRANOR) APPROVED IN THE EUROPEAN UNION AS FIRST NEW TREATMENT FOR PRIMARY BILIARY CHOLANGITIS IN NEARLY A DECADE APPROVAL FOLLOWS POSITIVE CHMP OPINION BASED ON ELATIVE PHASE III TRIAL DATA Source text for Workspace: ID:nGNX9KlXHf Furthe

Reuters - Il y a 1 mois

Cenbank divergences ending, apart from Japan - Amundi

LIVE MARKETS-Cenbank divergences ending, apart from Japan - Amundi STOXX 600 up 1.3% Fed cuts by 50 bps, eyes on BoE Ocado top index after results Miners, autos surge, utilities down Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com CENBANK DIVERGENCES ENDING, APART FROM JAPAN - AMUNDI It has been an eventful week for central bank activity.

Reuters - Il y a 1 mois

R&D picks in Europe

LIVE MARKETS-R&D picks in Europe STOXX 600 up 1.3% Fed cuts by 50 bps, eyes on BoE Ocado top index after results Miners, autos surge, utilities down Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com R&D PICKS IN EUROPE Research and development (R&D) has become a top priority for countries aiming to stay competitive in the global marketplace.

Reuters - Il y a 1 mois

European shares end marginally lower on tech drag; Fed in focus

UPDATE 2-European shares end marginally lower on tech drag; Fed in focus For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window France's Rexel jumps after rejecting $9.4 bln QXO bid UK insurer Phoenix falls on halting sale of unit SunLife STOXX 600 down 0.2% Updated at 1600 GMT By Shubham Batra and Shashwat Chauhan Sept 16 (Reuters) - Europe's STOXX 600 closed slightly lower on Monday as losses in heavyweight technology shares weighed on the in

Reuters - Il y a 1 mois

Tepid start for STOXX as miners weigh

LIVE MARKETS-Tepid start for STOXX as miners weigh STOXX 600 up 0.1% Miners down after China data M&A activity provides lifts Week's cenbank meetings loom Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com TEPID START FOR STOXX AS MINERS WEIGH The STOXX 600 .STOXX has kicked off the week hovering around flat, last up 0.1% after mostly flashing red for the first hour of trading.

Reuters - Il y a 1 mois

Ipsen rises after RBC ups on Iqirvo U.S. approval

BUZZ-Ipsen rises after RBC ups on Iqirvo U.S. approval ** Shares in Ipsen IPN.PA rise around 5% after RBC upgraded the French biopharma company to "outperform" from "sector perform", seeing mid-term support from Iqirvo (PBC) after its U.S. FDA approval in June ** The broker now sees peak sales for the primary biliary cholangiti treatment at 540 mil

Reuters - Il y a 1 mois

MTU Aero Engines, Nestle, Vusiongroup

EUROPE RESEARCH ROUNDUP- MTU Aero Engines, Nestle, Vusiongroup Sept 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including MTU Aero Engines, Nestle and Vusiongroup, on Monday. HIGHLIGHTS * Advanced Medical Solutions Group Plc AMSU.L : Peel Hunt raises target to 246p from 220p * MTU Aero Engines AG MTXGn.DE : Citigroup cuts to sell from neutral * Nestle SA NESN.S : Morgan Stanley cuts to underweight from equal-weight * Sodexo EXHO.PA : B

Reuters - Il y a 1 mois

Ipsen Provides Update On Contact-02 Phase III Trial

BRIEF-Ipsen Provides Update On Contact-02 Phase III Trial Sept 15 (Reuters) - Ipsen SA IPN.PA : IPSEN PROVIDES UPDATE ON CONTACT-02 PHASE III TRIAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FOLLOWING FINAL OVERALL SURVIVAL ANALYSIS IPSEN - TRIAL DEMONSTRATED A POSITIVE TREND TOWARDS IMPROVEMENT FOR ONE OF PRIMARY ENDPOINTS, BUT DID NOT MEE

Reuters - Il y a 1 mois

Employee of French drugmaker Ipsen to plead guilty to US insider trading

UPDATE 1-Employee of French drugmaker Ipsen to plead guilty to US insider trading Adds defense lawyer comment in paragraph 3 By Nate Raymond BOSTON, Sept 10 (Reuters) - An employee of French drugmaker Ipsen IPN.PA has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug developer Epizyme in 2022. Dishant Gupta, Ipsen's director of data strategy and operations, plans to plead guilty to securities

Reuters - Il y a 1 mois

Employee of French drugmaker Ipsen to plead guilty to US insider trading

Employee of French drugmaker Ipsen to plead guilty to US insider trading By Nate Raymond BOSTON, Sept 10 (Reuters) - An employee of French drugmaker Ipsen IPN.PA has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug developer Epizyme in 2022. Dishant Gupta, Ipsen's director of data strategy and operations, plans to plead guilty to securities fraud and is settling related claims by the U.S.

Reuters - Il y a 2 mois

Gilead gets US FDA approval for inflammatory liver disease drug

UPDATE 3-Gilead gets US FDA approval for inflammatory liver disease drug Adds pricing in paragraph 4, company comments in paragraphs 6-7, details on common symptom in paragraphs 10-12 By Puyaan Singh and Leroy Leo Aug 14 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.

Reuters - Il y a 3 mois

EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab)

BRIEF-EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab) July 26 (Reuters) - Biogen Inc BIIB.O EMA SAYS CHMP EXTENSIONS OF INDICATION FOR 11 MEDICINES THAT ARE ALREADY AUTHORISED IN THE EU INCLUDING AREXVY EMA SAYS CHMP RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) EMA SAYS CHMP RECOMME

Reuters - Il y a 3 mois

Ipsen drops on H1 results, as guidance hike already anticipated

BUZZ-Ipsen drops on H1 results, as guidance hike already anticipated ** Shares in Ipsen drop 6.8% after the French biopharma company announced H1 results ** "We expect shares to underperform," says Barclays, adding investors will focus on Sonatuline erosion risk and M&A. ** Broker notes disappointing miss from key growth driver Dysport ** Company also raised guidance to >7% CER growth, but this had already been anticipated by consensus, adds analyst ** Ipsen additionally announced exclusive ex-U

Reuters - Il y a 3 mois

Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor

BRIEF-Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor July 25 (Reuters) - Ipsen SA IPN.PA : IPSEN AND DAY ONE ENTER INTO EXCLUSIVE EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE TOVORAFENIB FOR THE MOST COMMON CHILDHOOD BRAIN TUMOR IPSEN SA - DAY ONE RECEIVES AP

Reuters - Il y a 3 mois

Ipsen And Day One Enter Into Exclusive Ex-U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor

Reuters - Il y a 3 mois

Ipsen Raises FY 2024 Guidance

BRIEF-Ipsen Raises FY 2024 Guidance July 25 (Reuters) - Ipsen SA IPN.PA : IPSEN DELIVERS STRONG RESULTS IN THE FIRST HALF OF 2024, PROGRESSES ON LAUNCHES AND UPGRADES ITS FULL-YEAR GUIDANCE H1 FREE CASH FLOW EUR 393.5 MILLION OUTLOOK 2024 UPGRADED: TOTAL-SALES GROWTH GREATER THAN 7.0%, AT CONSTANT CURRENCY OUTLOOK 2024 UPGRADED: CORE OPERATING MARG

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Ipsen

Actualités

Conditions

Actifs populaires

Chat en direct XM